La chaîne d'options affiche les données clés des options sur actions de Lixte Biotechnology à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Lixte Biotechnology..

Lixte Biotechnology (NASDAQ:LIXTW) Stock, Chaîne d'Options

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Lixte Biotechnology Holdings, Inc. - Warrants

Lixte Biotechnology Holdings Inc

Press Releases

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

LIXTE Biotechnology Holdings Provides Corporate Update

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

LIXT

LIXTW

Ainos

Azitra

BriaCell Therapeutics

Bio Green Med Solution, Inc. - 6% Convertible Preferred Stock

Bio Green Med Solution

Celularity

CERo Therapeutics Holdings, Inc. - Warrants

CERo Therapeutics Hldgs

Clene

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

ETHZilla

GT Biopharma

Lixte Biotechnology

Medicus Pharma

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics

Revolution Medicines

Sunshine Biopharma

Silexion Therapeutics

Surrozen

LIXTE BIOTECH HLD WT

Comments

Lixte Biotechnology

Lixte Biotechnology (LIXTW) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL